Yumi Kubo - Concepedia

Author

Yumi Kubo

Amgen (United States)ORCID

Also Known As

Yumi Kubo

Publications

944

Citations

H-Index

Concepts

All Affiliations

Amgen (United States)Stanford University University College London University of Minnesota Universitätsklinikum Aachen

About

Yumi Kubo is an author at Amgen (United States) specializing in pharmacotherapy, renal disease, and end-stage renal disease.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	1	1	122
2	Nephrology	1	1	122
3	Hemodialysis	1	1	122
4	Renal Disease	1	1	122
5	Chronic Kidney Disease	1	1	122

Yumi Kubo

Publications

930

Citations

H-Index

Page 1

	Year	Citations
Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis Sharon M. Moe, Glenn M. Chertow, Patrick S. Parfrey, Circulation	2015	299
The Effect of Cinacalcet on Calcific Uremic Arteriolopathy Events in Patients Receiving Hemodialysis Jürgen Floege, Yumi Kubo, Anna Floege, Clinical Journal of the American Society of Nephrology	2015	135
Effects of Cinacalcet on Atherosclerotic and Nonatherosclerotic Cardiovascular Events in Patients Receiving Hemodialysis: The EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) Trial David C. Wheeler, Gérard M. London, Patrick S. Parfrey, Journal of the American Heart Association	2014	135
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Cinacalcet HCl in Participants With CKD Not Receiving Dialysis Francesco Locatelli, H. E. Abboud, Ángel L.M. de Francisco, American Journal of Kidney Diseases HemodialysisUrologyRenal DiseaseRenal FunctionKidney Failure	2008	122
The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis Patrick S. Parfrey, Tilman B. Drüeke, Geoffrey A. Block, Clinical Journal of the American Society of Nephrology	2015	94
Phase 1, randomized, parallel-group, double-blind, placebo-controlled trial to evaluate the effects of erenumab (AMG 334) and concomitant sumatriptan on blood pressure in healthy volunteers Jan de Hoon, Anne Van Hecken, Corinne Vandermeulen, Cephalalgia	2018	45
Analyzing Health-Related Quality of Life in the EVOLVE Trial Andrew Briggs, Patrick S. Parfrey, Nasreen Khan, Medical Decision Making	2016	43
Assessing the treatment effect in a randomized controlled trial with extensive non‐adherence: the EVOLVE trial Yumi Kubo, Lulu Ren Sterling, Patrick S. Parfrey, Pharmaceutical Statistics	2015	22
Propensity score matching and persistence correction to reduce bias in comparative effectiveness: the effect of cinacalcet use on all‐cause mortality Iain Gillespie, Jürgen Floege, Ioanna Gioni, Pharmacoepidemiology and Drug Safety	2015	19
Relationship between Reductions in Parathyroid Hormone and Serum Phosphorus during the Management of Secondary Hyperparathyroidism with Calcimimetics in Hemodialysis Patients Kerry Cooper, L. Darryl Quarles, Yumi Kubo, Nephron Clinical Practice	2012	16

Page 1